Selpercatinib Monotherapy
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Differentiated Thyroid Cancer
Conditions
Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
Trial Timeline
Jul 29, 2024 → Nov 1, 2031
NCT ID
NCT06458036About Selpercatinib Monotherapy
Selpercatinib Monotherapy is a phase 2 stage product being developed by Eli Lilly for Differentiated Thyroid Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06458036. Target conditions include Differentiated Thyroid Cancer, Pediatric Cancer, Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06458036 | Phase 2 | Recruiting |
Competing Products
20 competing products in Differentiated Thyroid Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CAB-AXL-ADC + PD-1 inhibitor | BioAtla | Phase 1/2 | 33 |
| Abemaciclib + Placebo | Eli Lilly | Phase 3 | 77 |
| Lenvatinib + Placebo | Eisai | Phase 3 | 77 |
| Lenvatinib | Eisai | Pre-clinical | 23 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| LENVATINIB | Eisai | Phase 2 | 52 |
| Selumetinib + Placebo + Radioactive Iodine Therapy | AstraZeneca | Phase 3 | 77 |
| Pembrolizumab + Cisplatin + Docetaxel + Carboplatin | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| sunitinib + everolimus + chemotherapies recommended in france | Novartis | Pre-clinical | 23 |
| Everolimus + Sorafenib | Novartis | Phase 2 | 52 |
| Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placebo | Novartis | Phase 3 | 77 |
| PDR001 | Novartis | Phase 2 | 52 |
| Everolimus (Afinitor®) | Novartis | Phase 2 | 52 |
| Sacituzumab govitecan | Gilead Sciences | Phase 2 | 51 |
| sunitinib | Pfizer | Approved | 84 |
| Vandetanib (SAR390530) + Placebo | Sanofi | Phase 3 | 76 |
| Thyrogen (thyrotropin alfa for injection) | Sanofi | Phase 3 | 76 |
| Cabazitaxel | Sanofi | Phase 2 | 51 |
| Larotrectinib monotherapy | Bayer | Phase 2 | 49 |